Genovis AB: Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme
The milestone compensation is related to achieved development targets for the Xork enzyme that Genovis has out-licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases.
Xork is derived from a streptococcal bacterial strain that does not infect humans. The pre-clinical data generated to date highlights Xork's differentiated profile demonstrating very low cross-reactivity with naturally occurring antibodies in human sera while retaining efficient and specific cleavage of human IgG antibodies.